Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs